Industry News
Immutep granted Australian patent for Eftilagimod Alpha in combination with a PD-1 pathway inhibitor
Eftilagimod alpha, a soluble LAG-3 fusion protein is a first-in-class antigen presenting cell activator currently being explored in cancer and infectious disease